🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT06144996
Recruiting Observational

Development of a Canadian Bronchiectasis and NTM Database

NCT06144996 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Calgary
Phase
Observational
Started
2023-01-01
Last updated
2023-11-22

Condition(s) studied

BronchiectasisNon-Tuberculous Mycobacterial Pneumonia

Study summary

The investigators aim to develop a comprehensive patient registry of patients with non-CF bronchiectasis and/or Nontuberculosis Mycobacteria (NTM)

Eligibility

Sex
ALL
Min age
18 Years
Max age
120 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Over the age of 18 * Non-CF Bronchiectasis * Nontuberculosis Mycobacteria (NTM) Exclusion Criteria: * Under the age of 18 * CF bronchiectasis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting

More University of Calgary trials in Canada

A Novel Iron-Based Supplement for Athletes Aged 18-25: Phase II Active, not recruiting
Spinal Cord Stimulation for Blood Pressure Control in Hypertension Starting soon
CAlgary SAlt for POTS Recruiting
Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section. Recruiting
Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders Recruiting

Other trials for the same condition

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine Active, not recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06144996 on ClinicalTrials.gov ↗ ← All trials in Canada